The Latest Cardiac and Vascular News
– New shorter duration of dual anti-platelet therapy (DAPT) post XIENCE stent implant provides physicians with additional options to treat patients at high risk of bleeding – XIENCE is the most used drug eluting stent in the world, and European approval for shorter DAPT is supported by two studies that demonstrated safe treatment of stented […]
(GLOBE NEWSWIRE via COMTEX) —The Onyx ONE Clear Study Builds Upon Body of Clinical Evidence to Inform Individualized DAPT Duration Following Stent Procedures DUBLIN – September 10, 2018 – Medtronic plc (NYSE:MDT) today announced the start of the Onyx ONE Clear Study in the U.S. and Japan that will evaluate one-month dual antiplatelet therapy (DAPT) in […]
DUBLIN- August 14, 2017 – Medtronic plc (NYSE: MDT) today announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT) – the combination of aspirin and an anti-clotting medication – in patients implanted with the Resolute Onyx(TM) Drug-Eluting Stent (DES) during percutaneous coronary intervention (PCI). Designed to evaluate clinical DAPT outcomes between […]
PCRonline/News/Industry Press Releases – 04 April, 2017 MASTER-DAPT kicks-off with the enrolment of its first patient by Treant Zorggroep, Scheper Hospital Emmen, The Netherlands – Dr Gillian Jessurun from Treant Zorggroep, Scheper Hospital has enrolled the first patient in the investigator initiated MASTER DAPT (MAnagement of patients post bioresorbable polymer STEnt implantation with an abbreviated DAPT […]
